India Pharma Outlook Team | Tuesday, 17 November 2026
ESR1 mutation testing is gaining importance in breast cancer treatment following the US Food and Drug Administration's (FDA) approval of Roche's Wilserdly (giredestrant).
The oral drug, used with everolimus, is approved for adults with ESR1-mutated, oestrogen receptor-positive and HER2-negative locally advanced or metastatic breast cancer.
The FDA also authorized FoundationOne Liquid CDx as a companion diagnostic to identify eligible patients.
The decision highlights how molecular testing can help identify treatment-resistant cancers and guide therapy selection, strengthening the role of precision medicine in oncology.
Also Read: How Digital R&D Is Transforming API Development and cGMP Scale-Up in India
ESR1 mutations can cause resistance to hormone-based treatments in oestrogen receptor-positive breast cancer.
Roche estimates that these mutations affect up to 40 percent of patients with hormone receptor-positive metastatic breast cancer. ESR1 mutation testing helps identify patients carrying these mutations, allowing doctors to assess whether specific treatments may be suitable.
The FDA authorized FoundationOne Liquid CDx, which uses circulating tumour DNA (ctDNA) from blood samples to detect relevant ESR1 mutations. This makes molecular diagnostics an important part of treatment selection.
The approval was supported by the Phase III evERA trial involving 373 patients, including 207 with ESR1 mutations.
In the mutation-positive group, Wilserdly combined with everolimus reduced the risk of disease progression or death by 62 percent compared with standard endocrine therapy and everolimus.
Median progression-free survival was 10 months, against 5.5 months in the control group. Overall survival data were immature at the time of analysis.
The approval connects targeted treatment with molecular diagnosis. ESR1 mutation testing can help identify patients who may benefit from a specific treatment approach rather than relying only on conventional disease classification.
For Roche, the approval strengthens its position in breast cancer treatment and highlights the growing importance of companion diagnostics in personalized oncology.